Dassault Systèmes (DSY) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
23 Apr, 2026Executive summary
Q1 2026 delivered 3% revenue growth at constant currency, meeting objectives, with total revenue at €1.51 billion and strong performance in Mainstream Innovation, especially SOLIDWORKS and CENTRIC.
Recurring software revenue comprised 85% of total software revenue, with ARR up 6% year-over-year to €4.37 billion.
Growth was driven by 3DEXPERIENCE and Cloud, with 3DEXPERIENCE software revenue up to 42% of eligible software revenue and Cloud revenue up 8%.
Life Sciences and Consumer industries showed resilience despite sector headwinds, with tangible AI solutions launched across product lines.
Full-year 2026 non-IFRS objectives confirmed, leveraging Q1 achievements and focusing on accelerating the transition to subscriptions and industrial AI.
Financial highlights
Total revenue reached €1.51 billion, up 3% ex FX; software and services revenue both up 3% ex FX.
Operating cash flow was €949 million, up 22% ex FX, and free cash flow rose 27% ex FX to €899 million.
Upfront license revenue increased 9% ex FX due to significant multi-year deals.
Net cash position at €2.40 billion; cash and equivalents at €4.87 billion as of March 31, 2026.
IFRS operating margin at 23.0%; non-IFRS operating margin at 30.3%.
Outlook and guidance
Full-year 2026 non-IFRS revenue guidance: €6.29–6.41 billion (3%-5% growth ex FX), operating margin 32.2%-32.6%, EPS €1.30–1.34 (3%-6% growth ex FX).
Q2 2026 revenue expected at €1.518–1.568 billion (2%-5% growth ex FX), operating margin 29.5%-29.9%, EPS €0.29–0.31.
Acceleration in H2 expected, driven by improved year-over-year comparisons and pipeline strength in Americas and Asia.
Assumptions include EUR/USD at 1.18 and EUR/JPY at 173.37 for FY26.
Latest events from Dassault Systèmes
- Q2 revenue and EPS rose, cloud and AI advanced, ArisGlobal boosts Life Sciences growth.DSY
Q2 202625 Jul 2026 - Revenue and EPS rose, margins expanded, and Life Sciences strengthened by ArisGlobal acquisition.DSY
Q2 2026 Investor call23 Jul 2026 - Q3 revenue up 4% to €1.46B; FY EPS guidance reaffirmed, with Q4 growth acceleration expected.DSY
Q3 20249 Jul 2026 - FY25 revenue rose 4% to €6,240M, with ARR at €4.5B and FY26 growth targeted at 3–5%.DSY
Q4 2025 Investor Call9 Jul 2026 - Pascal Daloz takes over as Chairman and CEO as the company advances its Industrial AI strategy.DSY
Investor update8 Jul 2026 - Q1 2026 saw 3% revenue growth, strong cash flow, and confirmed full-year guidance.DSY
Q1 2026 Investor Call23 Apr 2026 - FY26 targets 3–5% revenue growth, margin expansion, and strong ARR momentum.DSY
Q4 202511 Feb 2026 - Revenue and EPS rose, with robust cloud and 3DEXPERIENCE growth; outlook remains strong.DSY
Q2 20249 Feb 2026 - Q2 revenue up 6%, guidance reaffirmed, strong 3DEXPERIENCE and cloud growth.DSY
Q2 20259 Feb 2026